5 Key Takeaways

• 1

  New drugs targeting episcleral venous pressure (EVP) show promise for improving glaucoma management and treatment outcomes.

• 2

  QLS-111, an ATP-sensitive potassium channel opener, effectively reduces EVP and intraocular pressure in clinical trials.

• 3

  Combining QLS-111 with latanoprost demonstrated significant additive effects in lowering intraocular pressure for stable patients.

• 4

  Innovative drug-delivery methods, including implants and 3D-printed lenses, aim to reduce the burden of glaucoma medication adherence.

• 5

  Future research in glaucoma may focus on neuroprotection and neuro-regeneration to address retinal ganglion cell death.